Aging and haemopoiesis: Implications for treatment with haemopoietic growth factors

Drugs and Aging

Volumn 9, Issue 1, 1996, Pages 37-47

  Chatta, Gurkamal S ^a   Dale, David C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AGED; AGING; ANEMIA; AUTOIMMUNITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG THERAPY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LYMPHOPOIESIS; MORBIDITY; MYELODYSPLASIA; NEOPLASM; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENESCENCE;

EID: 0030056469     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609010-00004     Document Type: Review

References (101)

1. Ben-Yehuda A, Weksler ME. Host resistance and the immune system. Clin Geriatr Med 1992; 8: 701-23
2. Saltzman RI, Peterson PK. Immunodeficiency of the elderly. Rev Infect Dis 1987; 9: 1127-39
3. Begg C, Carbone P. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986-92
4. Lipschitz D, Udupa K, Milton K, et al. Effect of age on hematopoiesis in man. Blood 1984; 63: 502-9
5. Baldwin JG. Hematopoietic function in the elderly. Arch Intern Med 1988; 148: 2544-6
6. Metcalf D. The molecular control of blood cells. Cambridge, Mass: Harvard University Press, 1988: 165
7. Spangrude GJ. Biological and clinical aspects of hematopoietic stem cells. Annu Rev Med 1994; 45: 93-104
8. Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis, Pt 3. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J Immunol 1984; 133: 157-64
9. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989; 169: 1721-31
10. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62: 124-31
11. Berenson RJ, Bensinger WI, Andrews RG, et al. CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951-5
12. Berenson RJ, Bensinger WI, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1711-22
13. Clark SC, Kamen R. The human hematopoietic colony stimulating factors. Science 1987; 236: 1229-37
14. Kaushansky K, Karplus PA. Hematopoietic growth factors: understanding functional diversity in structural terms. Blood 1993; 82: 3229-40
15. Zsebo K, Wypych J, McNiece I, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990; 63: 195-201
16. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-74
17. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-808
18. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568-71
19. Osslund T, Boone T. Biochemistry and structure of filgrastim (r-met-HuG-CSF). In: Morstyn G, Dexter TM. editors. Filgrastim (r-met-HuG-CSF) in clinical practice. New York: Marcel Dekker Inc., 1994: 23-31
20. Frampton JE, Yarker YE, Goa KL. Lenograstim: a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 1995; 49 (5): 767-93
21. Lieschke GJ, Burgess AW. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor. N Engl J Med 1992; 327: 28-35, 99-106
22. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 315: 164-70
23. Dale DC, Bonilla MA, Boxer LA, et al. A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-592
24. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after highdose chemotherapy. Blood 1993; 81: 2031-5
25. Schriber JR, Negrin RS. Use and toxicity of the colony-stimulating factors. Drug Saf 1993; 8: 457-68
26. Grant S, Heel R. Recombinant granulocyte-macrophage colony-stimulating factor (rGm-CSF): a review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43: 516-60
27. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339-44
28. Spivak JL. The clinical physiology of erythropoietin. Semin Hematol 1993; 4 Suppl. 6: 2-11
29. Paganini EP, Miller-T. Erythropoietin therapy in renal failure. Adv Intern Med 1993; 38: 223-43
30. Hirota Y, Okamura S, Kamura N, et al. Hematopoiesis in the aged as studied by in vitro colony assay. Eur J Hematol 1988; 40: 83-90
31. Boggs DR, Saxe DF, Boggs SS. Aging and hematopoiesis, Pt 2. The ability of bone marrow cells from young and aged mice to cure and maintain cure in W/Wv. Transplantation 1984; 37 (3): 300-6
32. Lee M, Segal G, Bagby G. The hematopoietic microenvironment in the elderly: defects in IL-I induced CSF expression in vitro. Exp Hematol 1989; 17: 952-6
33. Buchanan J, Rothstein G. Deficient growth factor production as a cause of hematopoietic dysregulation in aged subjects. Clin Res 1989; 37: 149-50
34. Chatta GS, Andrews RG, Rodger E, et al. Hematopoietic progenitors and aging: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. J Gerontol 1993; 48: M207-12
35. Chatta GS, Price TH, Dale DC, et al. The effects of in vivo rhG-CSF on the neutrophil response in healthy young and elderly volunteers. Blood 1994; 84: 2923-9
36. Nemunaitis J, Rosenfeld C. Mobilization of peripheral stem cells for transplantation. J Hematother 1993; 2: 351-5
37. Gray III TF, Shea TC. Current status of peripheral blood progenitor cell transplantation. Semin Oncol 1994; 21 (5 Suppl. 12): 93-101
38. Fennelly D, Vahdat L, Schneider J, et al. High-intensity chemotherapy with peripheral blood progenitor cell support. Semin Oncol 1994; 21 (2 Suppl. 2): 21-5
39. Sekhsaria S, Malech HL. Recombinant human stem cell factor enhances myeloid colony growth from human peripheral blood progenitors. Blood 1993; 81: 2125-30
40. Corberand J, Ngyen F, Laharrague P, et al. Polymorphonuclear functions and aging in humans. J Am Geriatr Soc 1981; 29: 391-7
41. MacGregor R, Shalit M. Neutrophil function in healthy elderly subjects. J Gerontol 1990; 45: M55-60
42. Timmafy M. A comparative study of bone marrow function in young and old individuals. Geront Clin (Basel) 1962; 4: 13-21
43. Cream JJ. Prednisolone-induced granulocytosis. Br J Haematol 1968; 15: 259-67
44. Chatta GS, Price TR, Stratton JR, et al. Aging and marrow neutrophil reserves. J Am Geriatr Soc 1994; 42: 77-81
45. Gardner ID, Lim TH, Lawton JWM. Monocyte function in aging humans. Mech Ageing Dev 1981; 16: 233-8
46. Weksler ME, Schwab R. The immunogenetics of immune senescence. Exp Clin Immunogenet 1992; 199: 182-7
47. Boggs DR, Patrene KD. Hematopoiesis and aging, Pt 3. Anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am J Hematol 1985; 19: 327-38
48. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of serum G-CSF in patients with infections. Blood 1990; 76: 1962-4
49. Kario K, Matsuo T, Nakao K. Serum erythropoietin levels in the elderly. Gerontology 1991; 37: 345-8
50. Carpenter MA, Kendall RG, O'Brien AE, et al. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 1992; 49: 119-21
51. Rothstein G, Christensen RD, Nielsen BR. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice. Blood 1987; 70: 1836-41
52. Rothstein G. Hematopoiesis in the aged: a model of hematopoietic dysregulation? Blood 1993; 82: 2601-4
53. Hayflick L. The cell biology of human aging. N Engl J Med 1976; 295: 1302-8
54. Norwood TH, Smith JR, Stein GH. Aging at the cellular level: the human fibroblast like cell model. In: Schneider EL, Rowe JW, editors. The handbook of the biology of aging, 3rd ed. New York: Academic Press Inc., 1990: 131-54
55. Goldstein S. Replicative senescence: the human fibroblast comes of age. Science 1990; 249: 1129-32
56. Mauch P, Botnick LE, Hannon EC, et al. Decline in bone marrow proliferative capacity as a function of age. Blood 1982; 60: 245-52
57. Grey HM, Sette A, Buus S. How T cells see antigen. Sci Am 1989; 261: 56-64
58. Mackall DL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 182-3
59. Weinberg K, Parkman R. Age, the thymus, and T lymphocytes. N Engl J Med 1995; 332: 143-9
60. Miller RA. The cell biology of aging: immunological models. J Gerontol 1989; 44: B4-8
61. Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one: a double-blind placebo-controlled clinical study. Clin Invest 1989; 37: 1
62. Gillis S, Kozan R, Durante M, et al. Decreased production of and response to T-cell growth factor by lymphocytes from aged humans. J Clin Invest 1981; 67: 937-62
63. Nagel J, Chopra R, Chrest F, et al. Decreased proliferation, IL-2 synthesis, IL-2 receptor expression are accompanied by decreased mRNA expression in PHA stimulated cells from elderly donors. J Clin Invest 1988; 81: 1096-1102
64. Ammann AJ, Schiffman G, Austrian R. The antibody responses to pneumococcal capsular polysaccharides in aged individuals. Proc Soc Exp Biol Med 1980; 164: 312-7
65. Radl J. Age-related monoclonal gammopathies. Immunol Today 1990; 11: 234-6
66. Bender BS. B lymphocyte function in aging. Rev Biol Research Aging 1985; 2: 143-8
67. Shank WA, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992; 40: 151-4
68. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-22
69. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82: 1454-61
70. Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 1989; 86: 9499-503
71. Duhrsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-81
72. Buchner T. Hematopoietic growth factors in cancer treatment. Stem Cells 1994; 12: 241-52
73. Dicke KA, Hood D, Hanks S. Peripheral blood stem cell collection after mobilization with intensive chemotherapy and growth factors. J Hematother 1994; 3: 141-4
74. Ozer H, American Society of Clinical Oncology ad hoc CSF Guidelines Expert Panel. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508
75. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994; 48: 731-60
76. Harmenberg J, Hoglund M, Hellstrom-Lindberg E. G-CSF and GM-CSF in oncology and oncological haematology. Eur J Haematol 1994; 55 Suppl.: 1-28
77. Markham A, Bryson HM. Epoetin alfa: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 1995; 49: 232-54
78. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-24
79. Vose JM. Cytokine use in the older patient. Semin Oncol 1995; 22 Suppl. 1: 6-8
80. Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 1988; 58: 64-9
81. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colonystimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; II: 891-5
82. Bronchud MH. Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: five years on. Oncology 1994; 51: 189-97
83. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96
84. Dale DC. Granulocyte colony stimulating factor in infectious diseases. Curr Opin Infect Dis 1993; 6: 369-73
85. Freireich EJ. White cell transfusions horn-again. Leuk Lymphoma 1994; 11: 161-5
86. Estey E. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994; 83: 2015-9
87. Hiddemann W, Wormann B, Reuter C. et al. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors. Semin Oncol 1994; 21 Suppl. 16: 33-8
88. Stone RM, Mayer RJ. The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 1993; 7: 65-79
89. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myeloid leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332: 1678-83
90. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebocontrolled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 1995; 86 (2): 457-62
91. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671-77
92. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773-8
93. Golumbek PT, Azhari R, Jaffee EM, et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993; 53: 5841-4
94. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994; 84: 997-1004
95. Greenberg PL. Use of recombinant human erythropoietin to treat the anemia of myelodysplastic syndromes. Semin Hematol 1993; 30 (4 Suppl.): 22S-4S
96. Boogaerts MA. Growth factors in haematology: prophylactic versus interventional use. Eur J Cancer 1994; 30A: 238-43
97. Andrews RG, Briddell RA, Knitter GH, et al. Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. Blood 1995; 85: 15-20
98. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86 (2): 419-31
99. Villareal DT, Morley JE. Trophic factors in aging: should older people receive hormonal replacement therapy? Drugs Aging 1994; 4 (6): 492-509
100. Shimon I, Shpilberg O. The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 1995; 19: 233-40
101. Vaziri H, Dragowska W, Allsopp RC, et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91: 9857-60